{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T08:39:16Z","timestamp":1792485556755,"version":"4.5.0"},"reference-count":39,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Calcitonin gene-related peptide (CGRP) is involved in the pathophysiology of cluster headache (CH). Prophylactic pharmacologic treatment options for chronic CH (CCH) are limited. The potential effects of erenumab, a CGRP receptor antagonist monoclonal antibody, in treating CCH have not been assessed.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate the superiority of erenumab compared with placebo in the prophylaxis of CCH.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>A 12-week, double-blind, placebo-controlled randomized clinical trial (CHERUB01) was conducted at 11 sites in Germany from December 2, 2021, to September 27, 2023. Participants (aged 18-65 years) had a diagnosis of CCH, had no previous sufficient response to standard CCH prophylactic medications approved in Germany, and had experienced at least 9 attacks during screening.<\/jats:p><\/jats:sec>Intervention<\/jats:title>Loading dose of erenumab (280 mg subcutaneously) or matching placebo in a 1:1 randomization, followed by another dose of erenumab (140 mg subcutaneously) or placebo 4 weeks later.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary end point was the reduction of mean weekly CH attacks from baseline over weeks 5 and 6. Key secondary end points were 50% responder rates and changes in Patient Global Impression of Improvement (PGI-I) scores. Safety and tolerability were also assessed. A bayesian analysis scheme was used for statistical analysis.<\/jats:p><\/jats:sec>Results<\/jats:title>This study randomized 81 participants (mean [SD] age, 48.9 [10.4] years; 60 men [74.1%]) with CCH (mean [SD], 21.5 [9.7] attacks per week) to erenumab (n\u2009=\u200941) or placebo (n\u2009=\u200940). Recruitment was stopped prematurely due to insufficient patient numbers meeting the inclusion criteria within the planned recruitment period. The primary end point was not met over weeks 5 and 6 of the double-blind phase because the mean (SD) reduction of weekly CH attacks was \u22127.3 (8.6) per week for erenumab and \u22125.9 (10.5) per week for placebo (group difference, \u22121.5 [95% credible interval [CrI], \u22125.7 to 2.8]). At weeks 5 and 6, the percentage of participants with a 50% or greater reduction in CH attacks was not significantly different between the erenumab (13 [31.7%]) and placebo (18 [45.0%]) groups (odds ratio, 0.5 [95% CrI, 0.2-1.5]). PGI-I scores were also not different between groups. More participants reported adverse events with erenumab than placebo (27 [65.9%] vs 17 [42.5%]), which were mostly of mild or moderate intensity.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this clinical trial of patients with CCH, blockade of the CGRP receptor with erenumab was not successful in the prophylaxis of attacks. Future studies should revisit the role of CGRP in CCH.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT04970355<\/jats:ext-link>; EudraCT Number: 2020-004399-16<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.16318","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T15:00:20Z","timestamp":1750172420000},"page":"e2516318","source":"Crossref","is-referenced-by-count":15,"title":["Erenumab for Chronic Cluster Headache"],"prefix":"10.1001","volume":"8","author":[{"given":"Jasper","family":"Mecklenburg","sequence":"first","affiliation":[{"name":"Department of Neurology, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Corporate Member of Free University and Humboldt University of Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charly","family":"Gaul","sequence":"additional","affiliation":[{"name":"Kopfschmerzzentrum Frankfurt, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Fitzek","sequence":"additional","affiliation":[{"name":"Department of Neurology, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Corporate Member of Free University and Humboldt University of Berlin, Berlin, Germany"},{"name":"Berlin Institute of Health, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas H.","family":"Overeem","sequence":"additional","affiliation":[{"name":"Department of Neurology, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Corporate Member of Free University and Humboldt University of Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Heinze","sequence":"additional","affiliation":[{"name":"Migr\u00e4ne und Kopfschmerzzentrum, Schmerzklinik Kiel, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Fleischmann","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Medicine Greifswald, Greifswald, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Boeger","sequence":"additional","affiliation":[{"name":"Schmerzzentrum Kassel, Kassel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagny","family":"Holle-Lee","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Medicine Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Straube","sequence":"additional","affiliation":[{"name":"Department of Neurology, Klinikum Gro\u00dfhadern, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, M\u00fcnchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Gendolla","sequence":"additional","affiliation":[{"name":"Praxis Gendolla, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Israel-Willner","sequence":"additional","affiliation":[{"name":"Neurologisches Facharztzentrum Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Lorenz","sequence":"additional","affiliation":[{"name":"Department of Neurology, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Corporate Member of Free University and Humboldt University of Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun","family":"Gossrau","sequence":"additional","affiliation":[{"name":"Comprehensive Pain Center, Faculty of Medicine, University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Naegel","sequence":"additional","affiliation":[{"name":"Department of Neurology, Universit\u00e4tsmedizin Halle, Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Rimmele","sequence":"additional","affiliation":[{"name":"Department of Neurology, Universit\u00e4tsmedizin Rostock, Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simrit","family":"Rattan","sequence":"additional","affiliation":[{"name":"Berlin Institute of Health, Berlin, Germany"},{"name":"Institute of Biometry and Clinical Epidemiology, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Corporate Member of Free University and Humboldt University of Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Materne","sequence":"additional","affiliation":[{"name":"Institute of Biometry and Clinical Epidemiology, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Corporate Member of Free University and Humboldt University of Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Schulze","sequence":"additional","affiliation":[{"name":"Institute of Biometry and Clinical Epidemiology, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Corporate Member of Free University and Humboldt University of Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Raffaelli","sequence":"additional","affiliation":[{"name":"Department of Neurology, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Corporate Member of Free University and Humboldt University of Berlin, Berlin, Germany"},{"name":"Berlin Institute of Health, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Reuter","sequence":"additional","affiliation":[{"name":"Department of Neurology, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Corporate Member of Free University and Humboldt University of Berlin, Berlin, Germany"},{"name":"Universit\u00e4tsmedizin Greifswald, Greifswald, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"CHERUB01 Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Burow","sequence":"additional","affiliation":[{"name":"for the CHERUB01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"G\u00f6bel","sequence":"additional","affiliation":[{"name":"for the CHERUB01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Kamm","sequence":"additional","affiliation":[{"name":"for the CHERUB01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Kl\u00f6tzer","sequence":"additional","affiliation":[{"name":"for the CHERUB01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"K\u00fchner","sequence":"additional","affiliation":[{"name":"for the CHERUB01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Lange","sequence":"additional","affiliation":[{"name":"for the CHERUB01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Neeb","sequence":"additional","affiliation":[{"name":"for the CHERUB01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Ruhnau","sequence":"additional","affiliation":[{"name":"for the CHERUB01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Ruscheweyh","sequence":"additional","affiliation":[{"name":"for the CHERUB01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Strau\u00df,","sequence":"additional","affiliation":[{"name":"for the CHERUB01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Zocholl","sequence":"additional","affiliation":[{"name":"for the CHERUB01 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"issue":"1","key":"zoi250511r1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"The International Classification of Headache Disorders, 3rd edition.","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","journal-title":"Cephalalgia"},{"issue":"7","key":"zoi250511r2","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/S1474-4422(24)00143-1","article-title":"Recent advances in diagnosing, managing, and understanding the pathophysiology of cluster headache.","volume":"23","author":"Petersen","year":"2024","journal-title":"Lancet Neurol"},{"issue":"1","key":"zoi250511r3","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s10194-023-01660-8","article-title":"Current treatment options for cluster headache: limitations and the unmet need for better and specific treatments\u2014a consensus article.","volume":"24","author":"Lund","year":"2023","journal-title":"J Headache Pain"},{"issue":"10","key":"zoi250511r4","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1111\/ene.15956","article-title":"European Academy of Neurology guidelines on the treatment of cluster headache.","volume":"30","author":"May","year":"2023","journal-title":"Eur J Neurol"},{"key":"zoi250511r5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104895","article-title":"A prospective open label 2-8 year extension of the randomised controlled ICON trial on the long-term efficacy and safety of occipital nerve stimulation in medically intractable chronic cluster headache.","volume":"98","author":"Brandt","year":"2023","journal-title":"EBioMedicine"},{"issue":"pt 3","key":"zoi250511r6","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/brain\/117.3.427","article-title":"Human in vivo evidence for trigeminovascular activation in cluster headache: neuropeptide changes and effects of acute attacks therapies.","volume":"117","author":"Goadsby","year":"1994","journal-title":"Brain"},{"issue":"2","key":"zoi250511r7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ana.410230214","article-title":"Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system.","volume":"23","author":"Goadsby","year":"1988","journal-title":"Ann Neurol"},{"issue":"10","key":"zoi250511r8","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1001\/jamaneurol.2018.1675","article-title":"Effect of infusion of calcitonin gene-related peptide on cluster headache attacks: a randomized clinical trial.","volume":"75","author":"Vollesen","year":"2018","journal-title":"JAMA Neurol"},{"issue":"11","key":"zoi250511r9","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/0028-3908(91)90165-8","article-title":"Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion.","volume":"30","author":"Buzzi","year":"1991","journal-title":"Neuropharmacology"},{"issue":"2","key":"zoi250511r10","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa1813440","article-title":"Trial of galcanezumab in prevention of episodic cluster headache.","volume":"381","author":"Goadsby","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi250511r11","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1177\/0333102420905321","article-title":"Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: results from 3-month double-blind treatment.","volume":"40","author":"Dodick","year":"2020","journal-title":"Cephalalgia"},{"issue":"1","key":"zoi250511r13","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s10194-022-01505-w","article-title":"Real-world experience with 240?mg of galcanezumab for the preventive treatment of cluster headache.","volume":"23","author":"Mo","year":"2022","journal-title":"J Headache Pain"},{"issue":"14","key":"zoi250511r14","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1177\/0333102420949866","article-title":"Effect of calcitonin gene-related peptide (-receptor) antibodies in chronic cluster headache: results from a retrospective case series support individual treatment attempts.","volume":"40","author":"Ruscheweyh","year":"2020","journal-title":"Cephalalgia"},{"issue":"22","key":"zoi250511r16","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","article-title":"A controlled trial of erenumab for episodic migraine.","volume":"377","author":"Goadsby","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi250511r17","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","article-title":"Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.","volume":"16","author":"Tepper","year":"2017","journal-title":"Lancet Neurol"},{"issue":"9","key":"zoi250511r18","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1007\/s11095-017-2183-6","article-title":"Pharmacokinetic-pharmacodynamic relationship of erenumab (AMG 334) and capsaicin-induced dermal blood flow in healthy and migraine subjects.","volume":"34","author":"Vu","year":"2017","journal-title":"Pharm Res"},{"issue":"5","key":"zoi250511r19","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/cpt.799","article-title":"Phase I, randomized, double-blind, placebo-controlled, single-dose, and multiple-dose studies of erenumab in healthy subjects and patients with migraine.","volume":"103","author":"de Hoon","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"zoi250511r20","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1177\/0333102420983282","article-title":"Migraine therapeutics differentially modulate the CGRP pathway.","volume":"41","author":"Bhakta","year":"2021","journal-title":"Cephalalgia"},{"issue":"1","key":"zoi250511r21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s10194-022-01425-9","article-title":"Characterization of erenumab and rimegepant on calcitonin gene-related peptide induced responses in Xenopus laevis oocytes expressing the calcitonin gene-related peptide receptor and the amylin-1 receptor.","volume":"23","author":"Hage La Cour","year":"2022","journal-title":"J Headache Pain"},{"issue":"2","key":"zoi250511r22","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231209317","article-title":"Pathophysiology of cluster headache: from the trigeminovascular system to the cerebral networks.","volume":"44","author":"Coppola","year":"2024","journal-title":"Cephalalgia"},{"issue":"1","key":"zoi250511r23","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1177\/2168479014533970","article-title":"Bayesian design of proof-of-concept trials.","volume":"49","author":"Fisch","year":"2015","journal-title":"Ther Innov Regul Sci"},{"issue":"1","key":"zoi250511r24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v080.i01","article-title":"brms: an R package for bayesian multilevel models using STAN.","volume":"80","author":"B\u00fcrkner","year":"2017","journal-title":"J Stat Softw"},{"issue":"5","key":"zoi250511r25","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1177\/0333102419837154","article-title":"Calcitonin-gene related peptide and disease activity in cluster headache.","volume":"39","author":"Snoer","year":"2019","journal-title":"Cephalalgia"},{"issue":"8","key":"zoi250511r26","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1177\/03331024211056248","article-title":"PACAP38- and VIP-induced cluster headache attacks are not associated with changes of plasma CGRP or markers of mast cell activation.","volume":"42","author":"Pellesi","year":"2022","journal-title":"Cephalalgia"},{"issue":"3","key":"zoi250511r27","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/nrd3923","article-title":"The placebo response in medicine: minimize, maximize or personalize?","volume":"12","author":"Enck","year":"2013","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"zoi250511r28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","article-title":"The blood-brain barrier: bottleneck in brain drug development.","volume":"2","author":"Pardridge","year":"2005","journal-title":"NeuroRx"},{"key":"zoi250511r29","first-page":"23","article-title":"The pharmacology of the novel 5-HT1-like receptor agonist, GR43175.","volume":"9","author":"Humphrey","year":"1989","journal-title":"Cephalalgia"},{"key":"zoi250511r30","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/205985","article-title":"Neural plasticity in common forms of chronic headaches.","volume":"2015","author":"Lai","year":"2015","journal-title":"Neural Plast"},{"issue":"12","key":"zoi250511r31","doi-asserted-by":"publisher","first-page":"5224","DOI":"10.1093\/brain\/awad261","article-title":"Second messenger signalling bypasses CGRP receptor blockade to provoke migraine attacks in humans.","volume":"146","author":"Do","year":"2023","journal-title":"Brain"},{"issue":"3","key":"zoi250511r32","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231226181","article-title":"Efficacy and safety of galcanezumab as chronic cluster headache preventive treatment under real world conditions: observational prospective study.","volume":"44","author":"Lamas P\u00e9rez","year":"2024","journal-title":"Cephalalgia"},{"issue":"5","key":"zoi250511r33","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1177\/0333102420970455","article-title":"Real-life treatment of cluster headache in a tertiary headache center: results from the Danish Cluster Headache Survey.","volume":"41","author":"Petersen","year":"2021","journal-title":"Cephalalgia"},{"issue":"1","key":"zoi250511r34","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.eplepsyres.2005.09.019","article-title":"Proof of principle studies.","volume":"68","author":"Schmidt","year":"2006","journal-title":"Epilepsy Res"},{"issue":"4","key":"zoi250511r35","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/head.14292","article-title":"Challenges and complexities in designing cluster headache prevention clinical trials: a narrative review.","volume":"62","author":"Dodick","year":"2022","journal-title":"Headache"},{"issue":"7","key":"zoi250511r36","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S1474-4422(21)00101-0","article-title":"Safety and efficacy of occipital nerve stimulation for attack prevention in medically intractable chronic cluster headache (ICON): a randomised, double-blind, multicentre, phase 3, electrical dose-controlled trial.","volume":"20","author":"Wilbrink","year":"2021","journal-title":"Lancet Neurol"},{"issue":"10","key":"zoi250511r37","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209349","article-title":"Efficacy and safety of erenumab in participants with episodic migraine in whom 2-4 prior preventive treatments had failed: LIBERTY 3-year study.","volume":"102","author":"Reuter","year":"2024","journal-title":"Neurology"},{"issue":"5","key":"zoi250511r38","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1111\/ene.14715","article-title":"Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial.","volume":"28","author":"Ashina","year":"2021","journal-title":"Eur J Neurol"},{"issue":"2","key":"zoi250511r39","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40259-024-00651-8","article-title":"Cardiovascular adverse drug reactions of anti-calcitonin gene-related peptide monoclonal antibodies for migraine prevention: an analysis from the European Spontaneous Adverse Event Reporting System.","volume":"38","author":"Sorbara","year":"2024","journal-title":"BioDrugs"},{"key":"zoi250511r12","unstructured":"A study comparing the efficacy and safety of fremanezumab (TEV-48125) for the prevention of chronic cluster headache (CCH). ClinicalTrials.gov identifier: NCT02964338. Updated November 9, 2021. Accessed December 16, 2024. https:\/\/clinicaltrials.gov\/study\/NCT02964338"},{"key":"zoi250511r15","unstructured":"A 1-year trial to inform about long-term exposure to eptinezumab in participants with chronic cluster headache (cCH) (CHRONICLE). ClinicalTrials.gov identifier: NCT05064397. Updated August 6, 2024. Accessed December 15, 2024. https:\/\/clinicaltrials.gov\/study\/NCT05064397"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2835406\/mecklenburg_2025_oi_250511_1749568856.02398.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T15:00:21Z","timestamp":1750172421000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2835406"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.16318","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,17]]}}}